ARTICLE | Emerging Company Profile
DTx: Optimizing RNA therapies for cellular uptake, biodistribution
Emerging Company Profile: DTx is slated to enter the clinic next year with its fatty acid ligand conjugated RNA therapy to treat retinitis pigmentosa
May 11, 2021 9:14 PM UTC
DTx is using fatty acid ligands to overcome delivery challenges for RNA therapies, starting with siRNAs.
When it comes to RNA therapeutics, co-founder CSO and CEO Arthur Suckow told BioCentury, “There are two problems. One is that cells don’t take up this class of therapeutics at all, so they need help to get in. The second challenge with them is that they are rapidly cleared by the kidney following injection into the body. Tissues beyond the liver and the kidney never see these drugs.”...
BCIQ Company Profiles
BCIQ Target Profiles